Tumor Mutation Burden Biomarker Inches Closer To Acceptance In Cancer
Data from AACR puts use of tumor mutation burden as biomarker for lung cancer outcomes in spotlight, but some experts argue the test is not ready for prime time.
Data from AACR puts use of tumor mutation burden as biomarker for lung cancer outcomes in spotlight, but some experts argue the test is not ready for prime time.